Clinical Obesity

OCT 8, 2026 · JOURNAL ARTICLE

Weight‐Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

Clinical Obesity

ABSTRACT While GLP‐1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues

SEP 21, 2026 · JOURNAL ARTICLE

Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index

Clinical Obesity

ABSTRACT Lipoedema is a painful adipose tissue disorder marked by disproportionate limb fat and often misclassified as generalized obesity or lymphoedema. This review examines its

SEP 13, 2026 · JOURNAL ARTICLE

Weight Reduction Heterogenicity and Mediators of GLP ‐ 1RAs and Dual Agonists for Individuals With Obesity: A Meta‐Analysis

Clinical Obesity

ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual agonists have become pivotal options for obesity, but marked weight loss heterogeneity remains poorly underst

AUG 12, 2026 · REVIEW

Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta‐Analysis

Clinical Obesity

Rigorous systematic review and meta-analysis with prespecified protocol (PRISMA 2020) across multiple study types and data sources, reporting clear null findings for depression, anxiety, and suicidal ideation with semaglutide, though high heterogeneity limits certainty.

AUG 5, 2026 · REVIEW

The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post‐Operative Neuropathic and Non‐Neuropathic Complications

Clinical Obesity

A systematic review of 12 studies confirming that post-operative neurological complications after bariatric surgery are real, heterogeneous, and largely preventable through nutritional management, but without novel interventional evidence or practice-changing new data.